Related Experiment Video
Updated: Jul 29, 2026
14:54
An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
Published on: October 20, 2018
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial
J F Tisdale1, D E Dunn, N Geller
1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. johntis@intra.niddk.nih.gov
Lancet (London, England)
|November 15, 2000
Summary
High-dose cyclophosphamide showed increased early mortality and infections in severe aplastic anemia patients compared to antithymocyte globulin (ATG). Standard ATG therapy appears safer and more effective for this condition.
Area of Science:
- Hematology
- Immunosuppression Therapy
- Clinical Trials
Background:
- Severe aplastic anemia (SAA) treatment traditionally involves immunosuppressive therapy.
- High-dose cyclophosphamide (HD-CTX) proposed as an alternative to antithymocyte globulin (ATG) for SAA.
- Previous studies suggested similar response rates for HD-CTX and ATG, with potential benefits in preventing relapse and clonal complications.
Purpose of the Study:
- To compare the efficacy and safety of HD-CTX plus cyclosporine versus conventional immunosuppression with ATG plus cyclosporine.
- To evaluate response rates in previously untreated patients with severe aplastic anemia.
- To assess secondary endpoints including relapse, clonal complications, disease-free survival, and overall survival.
Main Methods:
- Phase III, prospective, randomized trial involving 31 previously untreated SAA patients.
- Patients randomized to receive either HD-CTX (50 mg/kg/day for 4 days) or ATG (40 mg/kg/day for 4 days), both with cyclosporine.
- Primary endpoint: hematological response. Trial terminated early due to excess mortality in the HD-CTX group.
Main Results:
- Excess morbidity (invasive fungal infections) and early mortality observed in the HD-CTX group compared to the ATG group.
- No significant difference in overall response rates at 6 months (46% for HD-CTX vs. 75% for ATG).
- Median follow-up of 21.9 months; trial terminated prematurely.
Conclusions:
- HD-CTX appears to be a dangerous treatment choice for severe aplastic anemia due to increased risks of infection and early death.
- Standard immunosuppression with ATG plus cyclosporine demonstrates good results and appears safer.
- Longer follow-up is required to fully assess secondary endpoints like relapse, clonal complications, and survival.
